Please complete Pre-test

Chapter 1 of 2

 

 

Release Date: November 28, 2017
Expiration Date: November 28, 2018

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Due to the recent advances in the knowledge of molecular profiles, karyotyping, and the physiopathology of the disease, we are able to classify AML into different categories: favorable, intermediate, and adverse; all which have implications into the treatment and the outcome of the disease. View this activity and hear how Dr. Jabbour outlines the evolving treatment landscape and the identified subsets of AML that will help set the stage for treatment selection and sequencing. He will share with you an overview of the newly approved and emerging treatment options in clinical trials and offer insights into defining a new treatment plan in the era of expanded opportunities.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Review new agents recently approved in the treatment of AML, including safety, efficacy and side-effect profile to consider in treatment
  • Identify how new targeted agents in AML will impact the current treatment paradigm
  • Develop strategies to employ best practice for optimizing selection and sequencing of treatments

Agenda

The Evolving Treatment Landscape in AML – Elias Jabbour, MD

Instructions for Participation and Credit

This activity is eligible for credit through November 28, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Elias Jabbour, MD
Associate Professor
Section Chief, Acute Lymphocytic Leukemia
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Elias Jabbour received his medical degree from Saint Joseph University, Beirut, Lebanon, where he also completed his clinical residency. He completed a clinical fellowship in hematology-oncology at Gustave Roussy Institute, France, and clinical fellowships in leukemia and blood and marrow transplantation at The University of Texas MD Anderson Cancer Center. Dr. Jabbour is an Associate Professor and Section Chief, Acute Lymphocytic Leukemia, Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, Houston.

Dr. Jabbour is board certified by the Lebanese Board of Hematology, Lebanese Board of Oncology, and the American Board of Internal Medicine. He holds memberships in the Society of Hematologic Oncology, American Society of Bone Marrow Transplantation, American Society of Clinical Oncology, and the Lebanese Society of Medical Oncology. Dr. Jabbour is also a reviewer for World Journal of Hematology, Proceedings of the Mayo Clinic, Cancer, American Journal of Hematology, Bone Marrow Transplantation, Blood, Leukemia, Oncology Briefings, The Leukemia & Lymphoma Society, Journal of Clinical Oncology, Journal of Blood Disorders and Transfusion, and The New England Journal of Medicine. In addition, he has written hundreds of peer-reviewed original research articles, abstracts, and book chapters.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.

This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.



©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-173-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Elias Jabbour has disclosed no relevant financial relationships.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.